Market Reacts Negatively to MedTech Division Performance at Johnson & Johnson
Johnson & Johnson (JNJ) reported strong results from its pharmaceutical division, but the market reacted negatively due to underperformance in its MedTech segment. The stock dropped 2.7% despite beating revenue and earnings estimates as concerns arose over the stability of J&J's two-part growth strategy.